The human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor that belongs to the epidermal growth factor receptor (EGFR) family. Approximately 20--25% of breast cancers are characterised by HER2 protein overexpression or gene amplification, and such events are associated with poor prognosis ([@bib33]).

The humanised recombinant monoclonal antibody trastuzumab (Herceptin, Genentech, Inc., San Francisco, CA, USA) was the first HER2-targeting agent approved for clinical use in breast cancer ([@bib8]). In HER2-overexpressing or -amplified (HER2-positive) breast cancer patients, large phase III trials demonstrated that trastuzumab in combination with chemotherapy was significantly more effective than chemotherapy alone both in advanced disease and in adjuvant setting ([@bib34]; [@bib24]; [@bib28]; [@bib27]; [@bib32]). Although trastuzumab-based treatments represent today the standard approach for HER2-positive breast cancer, not all patients benefit from this therapy. In metastatic breast cancer (MBC) patients with high degree of HER2 expression, single-agent trastuzumab resulted in 35% response rate ([@bib36]), indicating that there is a considerable proportion of individuals potentially refractory to HER2 inhibition even in presence of the drug target. Moreover, one of the major clinical problems encountered with trastuzumab treatment is that MBC patients who initially respond to trastuzumab, show disease progression within 1 year from treatment initiation. A better knowledge of mechanisms responsible for primary and acquired resistance may improve prediction of trastuzumab sensitivity. Several mechanisms of resistance have been described to date, including co-expression of the truncated p95HER2 receptor ([@bib30]), activation of the phosphatidylinositol-3-kinase (PTEN/PI3K/AKT signalling pathway) ([@bib3]) and heterodimerisation with other growth factor receptors including MET ([@bib31]), but their clinical relevance is still debatable.

*MET* oncogene, localised on chromosome 7 and encoding the dimeric tyrosine kinase receptor for hepatocyte growth factor (HGF), is involved in cell proliferation, survival and angiogenesis ([@bib6]). *MET*-regulated invasive growth has a relevant role in cancer invasion and metastasis ([@bib5]). *MET* gene amplification has been described in many human cancers including lung ([@bib35]; [@bib7]), gastric ([@bib15]), oesophageal ([@bib22]) and endometrial cancer ([@bib29]), and correlates with aggressive disease and poor patient outcome ([@bib13]). In lung cancer, *MET* amplification is responsible for acquired resistance to anti-EGFR tyrosine kinase inhibitors in up to 20% of cases ([@bib11]). In breast cancer, MET and HGF overexpression correlates with short relapse-free and overall survival (OS) ([@bib38]; [@bib23]; [@bib39]; [@bib16]; [@bib9]; [@bib17]). In a recent study, [@bib26] reported that high levels of MET protein expression was associated with poor prognosis in early breast cancer. [@bib19] reported MET overexpression in 25% of HER2-positive breast tumours, supporting the hypothesis that both HER2 and MET receptors could synergise in promoting tumour growth. More recently, [@bib31] showed that MET contributes to trastuzumab resistance, and a subset of HER2-positive breast cancer patients may benefit from combined inhibition of both HER2 and MET.

Based on previous data, in the current study we aimed to investigate whether *MET* and *HGF* gene copy numbers (GCN) are associated with trastuzumab sensitivity in HER2-positive MBC patients.

Patients and methods
====================

Patient selection
-----------------

This retrospective study was conducted in a consecutive series of 130 HER2-positive MBC patients treated with trastuzumab in combination with chemotherapy or as a single agent in 13 centres in Italy and Poland. The HER2 status was determined locally and was defined as positive in presence of gene amplification detected by fluorescence *in situ* hybridisation (FISH) or in presence of high degree of expression (3+) by immunohistochemistry according to criteria described elsewhere ([@bib14]). *MET* and *HGF* GCN were evaluated on primary breast tumour tissue obtained at the time of surgery before any trastuzumab-based therapy. Main inclusion criteria adopted for patient selection included availability of primary breast cancer tumour tissue, possibility to verify the response according to RECIST criteria, and availability of clinical data including survival. The study was approved by the ethics committees of all local hospitals and was conducted in accordance with ethical principles stated in the most recent version of the Declaration of Helsinki or the applicable guidelines on good clinical practice, whichever represented the greater protection of the individuals.

Fluorescence *in situ* hybridisation analyses
---------------------------------------------

Unstained 4--5 *μ*m sections were subjected to a tri-colour FISH assay, using a probe cocktail including *HGF* sequences (RP11-554M24 labelled in Spectrum Gold), *MET* sequences (RP 11-95I20 labelled in Spectrum Red) and centromere 7 sequences (CEP7, labelled in Spectrum Green, Abbott Molecular, Denver, CO, USA). The FISH assays were performed according to previously described protocol ([@bib7]), including pre-treatment with 2 × SSC at 75 °C and digestion with Proteinase K for 5--20 min each, co-denaturation at 85 °C for 15 min, hybridisation for approximately 36 h and rapid post-hybridisation washes with 2 × SCC/0.4 NP40. Signals were enumerated in at least 50 tumour nuclei per specimen, using epifluorescence microscope with single interference filters at the following excitation/emission wavelengths: 350/460 for blue, 492/530 for green, 530/580 for gold and 572/625 for red, as well as dual (red/green) and triple (blue, red, green) band pass filters. For each slide, the mean and s.d. of copy number per cell of each tested DNA sequence, the percentage of cells with ⩽2, 3 and ⩾4 copies of each target and the ratio of *MET*/CEP7 and *HGF*/CEP7 were calculated. For documentation, images were captured using a CCD camera and merged using dedicated software (Leica Microsystems, Denver, CO, USA) ([Figure 1](#fig1){ref-type="fig"}).

*MET* FISH analysis was successfully performed in all 130 cases. Fluorescence *in situ* hybridisation analysis of *HGF* was only performed in 84 cases (64.6%), as adequate material was not available in 46 cases.

Lack of additional tumour sections did not allow us to perform additional biomarker analyses.

Statistical analyses
--------------------

The primary end point of the study was to assess whether increased *MET* and *HGF* GCNs affect sensitivity to trastuzumab in terms of failure rate. Patients were dichotomised into sensitive (complete or partial response and disease stabilisation) and refractory (evidence of progressive disease at the first imaging assessment). The cutoff for *MET* and *HGF* GCN discriminating between a positive or negative result was determined using a receiver operating characteristic analysis. Time to progression (TTP) was calculated from the date of first administration of trastuzumab to the date of progression or last assessment. Overall survival was calculated from the date of first administration of trastuzumab to the date of death or last contact. Differences in failure rate were compared by Fisher\'s exact test or *χ*^2^ test. Time to progression, OS and the 95% confidence intervals for the groups with negative and positive biomarker were evaluated by survival analysis using Kaplan--Meier method ([@bib18]), and compared using the log-rank test. Statistical significance was set at \<0.05 for each analysis. Multivariable analysis was performed using logistic regression analysis with a step-down procedure method, with response considered as independent variable. The model was built only on clinical variable, which were significantly associated with response rate at bivariate analysis.

Results
=======

Patient characteristics
-----------------------

A total of 130 HER2-positive MBC patients were included in this analysis. The vast majority of patients (*N*=109, 83.8%) received trastuzumab in combination with chemotherapy in first-line setting (*N*=82, 63%), most frequently in association with taxanes (paclitaxel 32.3%, docetaxel 20.8%). The remaining 21 patients (16.1%) received single-agent trastuzumab ([Table 1](#tbl1){ref-type="table"}). In the entire study population, response rate, including complete and partial response was 49.2%, median TTP was 9.4 months (range: 8.3--10.5 months) and median OS was 28.3 months (range: 22.6--33.9 months).

*MET* FISH results
------------------

No *MET* gene amplification (defined as ratio mean *MET*/mean CEP 7\>2) was detected and median mean *MET* GCN was 2.96 (range, 1.66--8.40 copies per cell). In two cases, an equivocal range (*MET*/CEP 7 ratio between 1.8 and 2) was observed (*MET*/CEP 7 ratio of 1.84 and 1.82, respectively). As illustrated in [Figure 2A](#fig2){ref-type="fig"}, receiver operating characteristic analysis identified a mean of 3.72 *MET* GCN as the optimal cutoff value for discriminating between sensitive and refractory patients. A total of 36 cases (27.7%) had mean *MET* ⩾3.72 (*MET* FISH positive) and 94 cases (72.3%) had mean *MET*\<3.72 (*MET* FISH negative). As shown in [Table 2](#tbl2){ref-type="table"}, *MET* FISH status was not associated with any clinical or biological characteristic. However, *MET* FISH-positive patients had a significantly higher failure rate (44.4% *vs* 16.0% *P*=0.001) and a significantly shorter TTP (median 5.7 *vs* 9.9 months; HR: 1.74; 95% CI 1.16--2.62; *P*=0.006) than *MET* FISH-negative patients ([Figure 3A](#fig3){ref-type="fig"}). *MET* FISH-positive patients had slightly shorter OS than *MET* FISH-negative patients (median 26.4 *vs* 29.1 months), but the difference was not statistically significant (HR: 1.12; 95% CI 0.65--1.93; *P*=0.681; [Figure 3B](#fig3){ref-type="fig"}). Importantly, a difference between *MET* FISH positive and *MET* FISH negative was observed in the small subgroup (*N*=21) of individuals treated with trasuzumab alone. In such subgroup, failure rate (20.0% *vs* 50.0%) and TTP (median 9.5 *vs* 1.9 months) were in favour of *MET* FISH-negative patients, even if, probably because of the small numbers, differences were not statistically significant (*P*=0.3 and *P*=0.2, respectively).

Fluorescence *in situ* hybridisation results of *HGF*
-----------------------------------------------------

Median mean *HGF* GCN was 2.80 (range, 1.14--6.90 copies per cell). As illustrated in [Figure 2B](#fig2){ref-type="fig"}, receiver operating characteristic analysis identified a mean of 3.01 *HGF* GCN as the optimal cutoff value for discriminating between sensitive and refractory patients. This cutoff split 33 cases (39.3%) as *HGF* FISH positive (mean *HGF* GCN ⩾3.01) and 51 cases (60.7%) as *HGF* FISH negative (mean *HGF* GCN\<3.01). As summarised in [Table 3](#tbl3){ref-type="table"}, *HGF* FISH status was not associated with any clinical characteristics, whereas there was a strong association between *HGF* and *MET* FISH status (*P*\<0.001): all *MET* FISH-positive cases resulted *HGF* FISH positive and all *HGF* FISH-negative cases were *MET* FISH negative. Patients who were *HGF* FISH positive had a significantly higher failure rate (30.3% *vs* 7.8% *P*=0.007) and a non-significantly shorter TTP (median 9.9 *vs* 10.5 months, HR 1.10 95% CI 0.70--1.74, *P*=0.665) than *HGF* FISH-negative patients (mean \<3.01; [Figure 4A](#fig4){ref-type="fig"}). Patients who were *HGF* FISH positive had a not statistically significant longer OS (median 35.2 *vs* 26.1 months, HR 0.83 95% CI 0.44--1.56, *P*=0.567) than *HGF* FISH-negative patients ([Figure 4B](#fig4){ref-type="fig"}).

*MET/HGF* FISH combination
--------------------------

To further investigate the impact of combined *MET* and *HGF* GCNs, we analysed the outcome of the 84 patients in whom both biomarkers were assessable. As illustrated in [Table 4](#tbl4){ref-type="table"}, overall results confirmed that failure rate was significantly lower in the population negative for both *MET* and *HGF* (*P*=0.007), with the percentage of progressing patients not significantly different than that detected with a single biomarker assay (failure rate: 7.8% in *MET* and *HGF* negative, 7.8% in *HGF* negative only and 16.0% in *MET* negative only).

Univariate and multivariate analysis
------------------------------------

To define which variables were predictive of trastuzumab sensitivity, clinical and biological characteristics, such as age (\<55 *vs* \>55 years), menopausal status (pre *vs* post), grade (2 *vs* 3), oestrogen receptor status (\<10% *vs* \>10%), progesterone receptor status (\<10% *vs* \>10%), proliferative activity (MIB1 \<10% *vs* \>10%), *MET* GCN (\<3.72 *vs* \>3.72) and *HGF* GCN (\<3.01 *vs* \>3.01) were evaluated in a univariate analysis, using trastuzumab failure rate as end point. Variables found significant in the univariate analysis (*MET* and *HGF* GCN) were included in the multivariate model. Because of the strong correlation between *MET* and *HGF*, multivariable model did not include both biomarkers at the same time. When *MET* was excluded, increased GCN of *HGF* resulted in a odds ratio of 5.87 (95% CI: 1.21--28.39, *P*=0.028). When *HGF* was not included, increased GCN of *MET* resulted in a odds ratio of 6.02 (95% CI: 2.24--16.8, *P*\<0.001).

Discussion
==========

The present study, the first evaluating the role of *MET* and *HGF* GCN in a large cohort of HER2-positive MBC patients treated with trastuzumab-based therapy, provides important evidence for the critical role of HGF/MET signalling pathway for sensitivity to anti-HER2 agents. Increased *MET* or *HGF* GCNs were detected in approximately one-fourth cases of HER2-positive breast cancer and were significantly associated with higher risk of treatment failure, supporting a role of anti-MET strategies in breast cancer. Predictive value of *MET* and *HGF* GCN was similar and combining both biomarkers did not increase sensitivity of the assay.

MET is a plasma membrane protein that relays signals from the extracellular environment into the cytoplasm, activated when its extracellular domain binds to HGF, also known as scatter factor. Recent data demonstrated that increased *MET* GCN represents a negative prognostic factor in human malignancies including lung ([@bib7]) and gastric cancer ([@bib13]). Preclinical and limited clinical data showed that *MET* amplification is an event responsible for resistance to agents interfering with the EGFR family. In lung cancer, two studies demonstrated that *MET* amplification occurs in approximately 15--20% of *EGFR*-mutant non-small-cell lung cancers with acquired resistance to the reversible EGFR tyrosine kinase inhibitors, gefitinib or erlotinib ([@bib2]; [@bib10]). In non-small-cell lung cancer, combination of anti-MET agents with anti-EGFR tyrosine kinase inhibitors (EGFR-TKIs) seems to be one of the most promising strategies to overcome acquired resistance to such agents ([@bib11]). Although in breast cancer *MET* is generally not focally amplified ([@bib31]), recent studies demonstrated a central role of *MET* in trastuzumab resistance. [@bib31] showed in a cell line model that attenuation of MET activity leads to sensitisation to trastuzumab, whereas MET activation protects cells from the growth inhibitory effects of trastuzumab by preventing trastuzumab-induced p27 induction. In addition, they showed that MET is co-expressed along with HER2 in HER2-overexpressing breast cancer cells and HER2-positive breast cancer samples. [@bib21] showed that high MET expression is associated with short progression-free survival in HER2-positive MBC patients treated with lapatinib, an irreversible EGFR and HER2 inhibitor. Our findings are in agreement with previous studies confirming that *MET* amplification is generally absent in breast cancer and that high *MET* GCN increases the risk of treatment failure ([@bib31]). Response and TTP favoured patients with no *MET* GCN gain, both in patients treated with trastuzumab plus chemotherapy and in patients treated with trazuzumab alone, supporting the potential therapeutic impact of anti-MET agents in MBC, particularly in combination with anti-HER2 agents.

Recently, [@bib25] showed that ARQ 197 (tivantinib), a c-MET inhibitor, significantly delays the onset and progression of bone metastases in *in vitro* and *in vivo* models, strongly suggesting that targeting c-MET may have therapeutic value in the treatment of MBC. In another study, [@bib20] characterised MET and HER expression and signalling in a panel of human tumour cell lines and demonstrated the differential susceptibility of these cell lines to single agents or combinations of foretinib, a multi-kinase MET inhibitor, with HER-targeted agents, erlotinib or lapatinib. Interestingly, *MET*-amplified lines with *EGFR* or *HER2* amplification were more sensitive to the combination of foretinib with lapatinib or erlotinib. Overall, these data suggest that therapy including a combination of anti-MET and anti-HER-targeted agents should be tested as a treatment option in HER2-positive patients with *MET*-amplified or -overexpressing tumours. The idea of combining trastuzumab with other targeted agents is not a new concept in breast cancer, as demonstrated in recent studies comparing trastuzumab with the combination of trastuzumab and pertuzumab, a novel anti-HER2 monoclonal antibody ([@bib1]; [@bib12]) or single-agent lapatinib with the association of trastuzumab and lapatinib in trastuzumab-refractory patients ([@bib4]).

Another interesting finding in our study was the strong association of *MET* and *HGF* GCN. To the best of our knowledge, this is the first study reporting such association in breast cancer. Moreover presence of increased GCN of both *MET* and *HGF* in the same tumours explains why a single test was equally predictive than the combination of both assays. Although *MET* activation can either occur through ligand-independent or ligand-dependent mechanisms ([@bib17]), our findings suggest that probably ligand-dependent MET activation could represent a relevant mechanism in HER2-positive breast cancer, indicating a potential role for anti-MET monoclonal antibodies in breast cancer. In a recent study, [@bib37] demonstrated that HGF autocrine expression correlated with phospho-MET levels in HGF autocrine cell lines and these cell lines showed high sensitivity to MET inhibition. Our findings together with that of [@bib37] data suggest that MBC patients with high HGF and MET levels could result particularly sensitive to MET therapeutics.

In conclusion, this large retrospective study showed that HGF/MET signalling pathway interferes with trastuzumab-based therapy sensitivity in HER2-positive MBC. These data, together with previous preclinical and clinical studies support further expansion of related studies and clinical development of anti-MET agents in combination with anti-HER2 compounds in HER2-positive MBC.
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![Hybridisation with the probe mix *MET* (Spectrum Red) *CEP7* (Spectrum Green) and *HGF* (Spectrum Gold) showing both *MET* and *HGF* low GCN in (**A**) and high GCN in (**B**). The color reproduction of this figure is available at the *British Journal of Cancer* online.](bjc2012335f1){#fig1}

![(**A**) Receiver operating characteristic (ROC) analysis identified a mean of 3.72 *MET* GCN as the optimal cutoff value discriminating sensitive and resistant population, associated with a sensitivity of 51.6% and a specificity of 79.8%. AUC (area under the curve) value was 0.679. (**B**) ROC analysis identified a mean of 3.01 *HGF* GCN as optimal cutoff value, associated with a sensitivity of 71.4% and a specificity of 67.1%. AUC (area under the curve) value was 0.663.](bjc2012335f2){#fig2}

![Time to progression (**A**) and survival (**B**) in *MET* FISH-positive and -negative patients, according to the cutoff of 3.72 GCN identified with the receiver operating characteristic (ROC) analysis. *MET* FISH-positive patients (*N*=36, 27.7%) had a significantly shorter time to progression (median 5.7 *vs* 9.9 months, HR 1.74; *P*=0.006) and a non-significant shorter survival (median 26.4 *vs* 29.1 months, HR: 1.12; *P*=0.681) than *MET* FISH-negative (*N*=94, 72.3%).](bjc2012335f3){#fig3}

![Time to progression (**A**) and survival (**B**) in *HGF* FISH-positive and -negative patients, according to the cutoff of 3.01 GCN identified with the receiver operating characteristic (ROC) analysis. *HGF* FISH-positive patients (*N*=33, 39.3%) had a not significant shorter time to progression (median 9.9 *vs* 10.5 months, HR 1.10; *P*=0.665) and a longer, not statistically significant, survival (median 35.2 *vs* 26.1 months, HR 0.83; *P*=0.567) than *HGF* FISH-negative patients (*N*=51, 60.7%).](bjc2012335f4){#fig4}

###### Patient characteristics

  **Characteristics**                  **Total**      **%**
  ---------------------------------- ------------- -----------
  Total no. of patients                   130          100
  Median age, years (range)           55 (33--80)        
                                                         
  *Menopausal status*                              
   Available/not available              104/26        80/20
   Premenopausal/postmenopausal          18/86      17.3/82.7
                                                         
  *Histology*                                      
   Invasive ductal carcinoma              114         87.7
   Invasive lobular carcinoma              8           6.1
   Other types                             8           6.1
                                                         
  *Grade*                                          
   2                                      47          36.1
   3                                      68          52.3
   Not defined                            15          11.5
                                                         
  *Hormonal status (IHC)*                          
   ER value ⩾10%                          52           40
   PgR value ⩾10%                         43           33
                                                         
  *MiB1/Ki67*                                      
   Available/not available               47/83      36.1/63.8
   Value ⩾10%                             44          93.6
                                                         
  *HER2+ (IHC/FISH)*                               
   IHC 3+ and FISH not done               76          58.5
   IHC 2+ and FISH amplified               6           4.6
   IHC 3+ and FISH amplified              48          36.9
                                                         
  *Treatment*                                      
   Trastuzumab monotherapy                21          16.1
   Trastuzumab with chemotherapy          109         83.8
                                                         
  *Line of treatment*                              
   First line                             82           63
   Second line                            37          28.5
   Third or subsequent lines              11           8.5
                                                         
  *Drug combined with trastuzumab*                 
   None                                   21          16.1
   Paclitaxel                             42          32.3
   Docetaxel                              27          20.8
   Vinorelbine                            25          19.2
   Other                                  15          11.5

Abbreviations: MBC=metastatic breast cancer; ER=oestrogen receptor; PgR=progesterone receptor; HER2+=human epidermal growth factor receptor 2 positive (overexpression and/or amplification); IHC=immunohistochemistry; FISH=fluorescent *in situ* hybridisation.

###### Association between *MET* gene copy number and clinical and biological characteristics in HER2-positive metastatic breast cancer patients (*N*=130)

  **Characteristic**           ***MET*** **FISH + (*****N***** / %)**   ***MET*** **FISH − (*****N*** **/ %)**   ***P*****-value**
  --------------------------- ---------------------------------------- ---------------------------------------- -------------------
  All                                         36/27.7                                  94/72.3                            
  Age ⩾55 years                               17/47.2                                  47/50.0                         0.777
  Age \<55 years                              19/52.8                                  47/50.0                            
  Premenopausal                                6/19.4                                  12/16.4                         0.719
  Postmenopausal                              25/80.6                                  61/83.6                            
  Invasive ductal carcinoma                   33/91.7                                  81/86.2                         0.554
  Other histology                              3/8.3                                   13/13.8                            
  Grade 2                                      9/29.0                                  38/45.2                         0.117
  Grade 3                                     22/71.0                                  46/54.8                            
  IHC ER value ⩾10%                           15/41.7                                  37/39.4                         0.810
  IHC ER value \<10%                          21/58.3                                  57/60.6                            
  IHC PgR value ⩾10%                          12/33.3                                  31/33.0                         0.969
  IHC PgR value \<10%                         24/66.7                                  63/67.0                            
  MiB1/Ki67 value ⩾10%                        35/97.2                                  92/97.9                         1.000
  MiB1/Ki67 value \<10%                        1/2.8                                    2/2.1                             

Abbreviations: *MET=*mesenchymal-epithelial transition factor; HER2=human epidermal growth factor receptor 2; ER=oestrogen receptor; PgR=progesterone receptor; IHC=immunohistochemistry; FISH=fluorescent *in situ* hybridisation.

###### Association between *HGF* gene copy number and clinical and biological characteristics in HER2-positive metastatic breast cancer patients (*N*=84)

  **Characteristic**           ***HGF*** **FISH + (*****N*** **/ %)**   ***HGF*** **FISH − (*****N*** **/ %)**   ***P*****-value**
  --------------------------- ---------------------------------------- ---------------------------------------- -------------------
  All                                         33/39.3                                  51/60.7                            
  Age ⩾55 years                               17/51.5                                  26/51.0                         0.962
  Age \<55 years                              16/48.5                                  25/49.0                            
  Premenopausal                                  0                                      4/11.1                         0.287
  Postmenopausal                               22/100                                  32/88.9                            
  Invasive ductal carcinoma                   28/84.8                                  43/84.3                         0.947
  Other histology                              5/15.2                                   8/15.7                            
  Grade 2                                      9/32.1                                  23/51.1                         0.112
  Grade 3                                     19/67.9                                  22/48.9                            
  IHC ER value ⩾10%                           13/39.4                                  19/37.3                         0.844
  IHC ER value \<10%                          20/60.6                                  32/62.7                            
  IHC PgR value ⩾10%                           9/27.3                                  17/33.3                         0.557
  IHC PgR value \<10%                         24/72.7                                  34/66.7                            
  MiB1/Ki67 value ⩾10%                         33/100                                  50/98.0                         1.000
  MiB1/Ki67 value \<10%                          0                                      1/2.0                             
  *MET* FISH +                                21/63.6                                     0                           \<0.001
  *MET* FISH −                                12/36.4                                   51/100                            

Abbreviations: *HGF*=hepatocyte growth factor; FISH=fluorescent *in situ* hybridisation; *MET*=mesenchymal-epithelial transition factor; HER2=human epidermal growth factor receptor 2; ER=oestrogen receptor; PgR=progesterone receptor; IHC=immunohistochemistry.

###### Outcome according to *MET* and *HGF* GCN

              **Biomarker**     ***N***   **Failure rate (*****N***** / %)**   **TTP (months)**   **OS (months)**
  ----------- ---------------- --------- ------------------------------------ ------------------ -----------------
  A           *MET*+/*HGF*+       21                    6/28.6                       9.2               26.4
  B           *MET*+/*HGF*−        0                     ---                         ---                ---
  C           *MET*−/ *HGF*+      12                    4/33.3                       10.3              48.8
  D           *MET*−/*HGF*−       51                    4/7.8                        10.5              26.1
  *P*-value   A *vs* C                                   1.0                         0.2                0.4
              A *vs* D                                  0.054                        0.2                0.9
              A+C *vs* D                                0.007                        0.7                0.6

Abbreviations: TTP=time to progression; OS=overall survival; *MET*=mesenchymal-epithelial transition factor; *HGF*=hepatocyte growth factor.

[^1]: For the Central and East European Oncology Group (CEEOG).
